3.10
+2.31%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About SAB Biotherapeutics
From its filings with the US Securities and Exchange Commission
SAB Biotherapeutics is based in Miami Beach, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SABS. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and net income of $13.3m. At that date it held total assets of $172.8m and shareholders' equity of $151.5m.
We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs. We are focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets or best-in-class against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. The Company’s lead candidate, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to potentially change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients.
Using advanced genetic engineering and antibody science, we developed a proprietary technology which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. We believe it is the only technology capable of producing disease-targeted, hIgG in large quantities without human plasma donors.
Quoted from its 10-K, filed 9 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Jan 2021
- Employees
- 86
- Website
- sab.bio ↗
- Head office
- 777 W 41ST ST, MIAMI BEACH, FL, 33140
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. David ZaccardelliChairman of the Board, since 2026
- Dr. Eddie SullivanPresident, Director, since 2014$1.6m
- Mr. Samuel ReichChief Executive Officer, Director, since 2021$2.6m
- Mr. David LinkIndependent Vice Chairman of the Board$98,558
- Ms. Lucy ToChief Financial Officer$404,431
- Dr. Christoph BauschChief Operating Officer$1.2m
- Dr. Alexandra KropotovaChief Medical Officer$1.3m
- Ms. Katie ElliasIndependent Director$180,452
- Rear Adm. (Retd.) Scott GibersonIndependent Director$76,072
- Dr. Rita JainIndependent Director
- Mr. Erick LuceraIndependent Director$81,322
- Mr. Andrew MoinIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- SAB Biotherapeutics employs 56 full-time staff members in the US.
- The company utilizes the DiversitAb platform for serious human diseases.
- SAB-185 targets coronavirus disease with fully human polyclonal antibodies.
Weaknesses
- The firm has only 86 employees listed in the data.
- Operations are concentrated in Sioux Falls, South Dakota.
- The company went public on 12 January 2021 recently.
Opportunities
- SAB-176 binds to Type A and B influenza viruses.
- SAB-195 treats Clostridioides difficile infection as first-in-class asset.
- SAB-142 addresses organ transplant rejection and induction indications.
Threats
- The sector is Health Care with high regulatory scrutiny.
- Biotechnology industry requires extensive clinical-stage development resources.
- Competitors may develop similar immunotherapeutic polyclonal human antibodies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.